Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.58 |
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27654714 | 0.95 | CTSV (0.58) | CTSVCTSLMCL1POLBSENP8 | |
| SCHEMBL8316504 | 0.91 | CTSV (0.61) | CTSVCTSLMCL1POLBSENP8 | |
| SCHEMBL28257932 | 0.89 | CTSV (0.63) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL19035902 | 0.86 | CTSV (0.57) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL31235825 | 0.86 | CTSV (0.60) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL582235 | 0.86 | CTSV (0.60) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL7038843 | 0.85 | MAOB (0.53) | CTSVCTSLTDP1L3MBTL1CYP19A1 | |
| SCHEMBL873861 | 0.85 | CTSV (0.60) | CTSVCTSLSENP8SENP7SENP6 | |
| SCHEMBL159283 | 0.85 | CTSV (0.60) | CTSVCTSLSENP8SENP7SENP6 | |
| SCHEMBL31738283 | 0.84 | CTSV (0.58) | CTSVCTSLMCL1POLBSENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5994539-A | Mercapto acyl aminoacid derivatives endowed with dual ACE-NEP inhibitory activity, useful in the treatment of cardiovascular diseases | ZAMBON GROUP S.P.A. (IT) | 1999-11-30 | — | — | US | claimed |
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-13 | — | — | US | disclosed |
| CN-100404517-C | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | CN | disclosed |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-23 | — | — | US | disclosed |
| EP-1163227-B1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-28 | — | — | EP | disclosed |
| EP-0877740-B1 | THIOL DERIVATIVES WITH METALLOPEPTIDASE INHIBITORY ACTIVITY | ZAMBON SPA (IT) | 2005-03-30 | — | — | EP | disclosed |
| CN-1150171-C | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for their preparation | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-05-19 | — | — | CN | disclosed |
| US-6656946-B2 | For treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| CN-1449390-A | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-10-15 | — | — | CN | disclosed |
| EP-1315705-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM ZENTRALE GMBH (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-11-28 | — | — | US | disclosed |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | US | disclosed |
| CN-1343201-A | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-04-03 | — | — | CN | disclosed |
| WO-2002018351-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
| EP-1163227-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055141-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | disclosed |
| US-5994539-A | Mercapto acyl aminoacid derivatives endowed with dual ACE-NEP inhibitory activity, useful in the treatment of cardiovascular diseases | ZAMBON GROUP S.P.A. (IT) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203683-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM | REN, APC, PKD1 | CTSV 2604/4885CTSL 2785/4885MCL1 2407/4885 |
| US-20060063752-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | REN, APC, PKD1 | CTSV 2604/4885CTSL 2785/4885MCL1 2407/4885 |
| US-20020177601-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, BDKRB1 | CTSV 3357/4885CTSL 3264/4885MCL1 2324/4885 |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | CTSV 4740/4885CTSL 4369/4885MCL1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.